| 马晨瑜,邓旻.急性心肌梗死尿激酶原静脉溶栓临床研究进展[J].浙江中西医结合杂志,2021,31(3): |
| 急性心肌梗死尿激酶原静脉溶栓临床研究进展 |
| Clinical research progress of intravenous thrombolysis with prourokinase in acute myocardial infarction |
| 投稿时间：2020-07-16 修订日期：2020-11-10 |
| DOI： |
| 中文关键词: 尿激酶原 急性心肌梗死 溶栓治疗 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 495 |
| 全文下载次数: 1 |
| 中文摘要: |
| 急性心肌梗死（AMI）是冠心病最为严重的一种类型，因发病率及病死率高，严重威胁着患者的生命。临床上尤其是基层医疗机构对于急性心肌梗死的急救治疗仍多采用溶栓手段进行。因此应用一种安全有效的溶栓药物对急性心肌梗死患者预后恢复具有重要的意义，本文就尿激酶原在急性心肌梗死中的临床应用及溶栓治疗做一综述，为临床上尿激酶原的安全应用提供依据。 |
| 英文摘要: |
| Acute myocardial infarction is a common emergency critical disease. If not treated in time, it can lead to death and seriously threaten the life safety of patients. At present, the treatment of acute myocardial infarction includes coronary artery bypass surgery, interventional surgery, drug thrombolysis. Thrombolysis is easy to operate, economical, simple and fast. It plays an important role in the treatment of acute myocardial infarction especially in primary health care institutions. Pro-urokinase is a new type of specific thrombolytic drug, which belongs to the precursor of urokinase and has low catalytic activity. When it is transported to the thrombus, it can be activated by fibrinolytic enzyme, open the peptide chain to form urokinase, and play its role. In this paper, the clinical application and thrombolysis of urokinase in acute myocardial infarction are reviewed, which provides a reference for the safe application of urokinase in clinical. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
